This study is not yet accepting patients

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

a study on Fibrosis Idiopathic Pulmonary Fibrosis

Summary

Eligibility
for people ages 40-85 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Harold Chapman, MD
Headshot of Harold Chapman
Harold Chapman

Description

Summary

The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.

Official Title

Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect

Details

This is a multi-center, double-blind, placebo-controlled, dose-ranging Phase I study of once daily EGCG administered for 12 weeks. The study will assess safety, pharmacokinetics, and biomarker measurements of drug effect in IPF patients already receiving background therapy for IPF with either nintedanib or pirfenidone. Two different doses of EGCG will be studied. The rationale for this study is 1) extensive pre-clinical data in mice that EGCG is efficacious in attenuating pulmonary fibrosis by blocking collagen cross-linking and the pro-fibrotic pathway mediated by TGFβ1 signaling and 2) recently published data demonstrating that in humans EGCG is safe and capable of blocking lung tissue pro-fibrotic signaling when given two weeks prior to diagnostic surgical biopsy of pulmonary fibrosis patients, many of whom were subsequently diagnosed with IPF.

Keywords

Idiopathic Pulmonary Fibrosis, epigallocatechin-3-gallate, EGCG, Pulmonary Fibrosis, Fibrosis, Pirfenidone, Nintedanib, Epigallocatechin gallate, EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone

Eligibility

You can join if…

Open to people ages 40-85

  1. Provision of signed and dated informed consent form.
  2. Stated willingness to comply with all study procedures and availability for the duration of the study.
  3. Male or female, aged 40-85 years old
  4. Participant has IPF satisfying the 2022 ATS diagnostic criteria, confirmed by enrolling investigator at Visit 1.
  5. Participant must have been on a stable dose of nintedanib or pirfenidone for at least 12 weeks prior to baseline (Visit 2).
  6. Participant has a FVC ≥ 50% predicted using the global lung function initiative (GLI)
  7. Participant has a DLCO corrected for hemoglobin ≥ 35% predicted using the GLI
  8. Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if < 55 years or 12 months if > 55 years, must have a negative serum pregnancy test within 1 week prior to the first dose of study drug and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception include use of oral contraceptives or Depo-Provera, with an additional barrier method (diaphragm with spermicidal gel or condoms with spermicide), double-barrier methods (diaphragm with spermicidal gel and condoms with spermicide), partner vasectomy, and total abstinence.
  9. Participant has a life expectancy of at least 9 months at Visit 1.
  10. . Ability to take oral medication and be willing to adhere to EGCG regimen.
  11. . Agreement to refrain from drinking green tea in excess of a cup a day or eating green tea extract for 4 weeks before baseline and during the trial.

You CAN'T join if...

  1. AST, ALT, or direct bilirubin above upper limit normal from any cause at the Screening Visit
  2. Any history of HCV or HBV infection, NASH/NAFLD, or cirrhosis
  3. Alcohol consumption greater than 7 drinks per week
  4. Participant has emphysema ≥ 50% or the extent of emphysema is greater than the extent of fibrosis as per interpretation of Site Investigator or radiologist
  5. Participant has received investigational therapy for IPF within 4 weeks before baseline (Visit 2)
  6. Participant is receiving systemic corticosteroids equivalent to prednisone > 10 mg/day or equivalent within 2 weeks of baseline visit (Visit 2)
  7. Participant has any concurrent condition other than IPF that, in the Investigator's opinion, is unstable and/or would impact the likelihood of survival for the study duration or the participant's ability to complete the study as designed, or may influence any of the safety or efficacy assessments included in the study.
  8. Participant has baseline resting oxygen saturation of < 89% on room air or need for continuous oxygen use at baseline visit (Visit 2).
  9. Consumption of GTE products in excess of a cup of green tea a day within one month of the baseline visit (Visit 2).
  10. . Participant is receiving digoxin at the time of screening (Visit 1) and for the duration of the study.
  11. . Active respiratory infection requiring treatment with antibiotics within 4 weeks of the baseline visit (Visit 1).

Locations

  • UCSF Parnassus
    San Francisco California 94143 United States
  • Cornell University
    New York New York 10065 United States

Lead Scientist at UCSF

  • Harold Chapman, MD
    I have had a longstanding interest and productive history in the field of tissue remodeling, particularly as it relates to lung disease and have been continuously RO1 funded since 1991. I have also had virtually two research lives. For many years my work primarily focused on proteolytic enzymes.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Hal Chapman
ID
NCT05195918
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 50 study participants
Last Updated